Hansoh Pharma Reports H1 2024 Net Profit More Than Doubles, Innovative Products Contribute Over 77% of Revenue

China Economic Net Beijing, August 28th, by reporter Guo Wenpei — On August 27th, Hansoh Pharma released its 2024 interim performance report, continuing to demonstrate leading advantages in innovative drug research and development, commercialization, and corporate operations. "Innovation + Internationalization" has become a new driving force for its long-term sustainable growth. During the reporting period, the company achieved revenue of approximately 6.506 billion yuan, representing a year-on-year increase of about 44.2%; net profit was approximately 2.726 billion yuan, reflecting a year-on-year increase of about 111.5%.

Specifically, thanks to the continuous growth of a diversified innovative product portfolio and the steady progress of global collaborations, in the first half of 2024, the revenue from Hansoh Pharma's innovative drugs and collaborative products reached approximately RMB 5.032 billion, representing a year-on-year increase of about 80.6%, with the proportion of total revenue rising to 77.4%. By therapeutic area, during the reporting period, the Company recorded revenues of approximately RMB 4.475 billion, RMB 701 million, RMB 733 million, and RMB 597 million in anti-tumor, anti-infective, central nervous system, metabolic and other disease areas, respectively, accounting for approximately 68.8%, 10.8%, 11.3%, and 9.1% of total revenue.

Notably, as of the end of the reporting period, all seven innovative drugs launched by Hansoh Pharma and their corresponding nine indications have been included in the National Medical Insurance Catalog.

In terms of R&D investment, in the first half of 2024, Hansoh Pharma's R&D expenditure was approximately 1.196 billion yuan, increasing by about 28.7% year-on-year, accounting for approximately 18.4% of total revenue. The company currently has more than 30 innovative drugs undergoing over 50 clinical trials, with significant progress achieved in the development of several key products. For instance, the New Drug Application (NDA) for the third and fourth indications (adjuvant treatment for NSCLC and maintenance therapy for unresectable stage III NSCLC patients following concurrent chemoradiotherapy) of Almonertinib, China’s first domestically developed third-generation EGFR-TKI, were successively accepted by the National Medical Products Administration (NMPA). Previously, Almonertinib had already been approved for two indications: second-line treatment of EGFR T790M+ advanced NSCLC and first-line treatment of EGFR+ advanced NSCLC, both as the first China-produced drug to receive approval, demonstrating a clear first-mover advantage.

Through the efficient collaboration of independent research and external cooperation, Hansoh Pharma has continued to deeply cultivate the oncology sector since the beginning of this year. The company is scientifically exploring global potential pipelines and accelerating the layout in areas such as anti-infectives, central nervous system, metabolism, and autoimmune diseases. As of the end of the reporting period, the company has cumulatively introduced 11 cooperative projects, with 9 in clinical stages and the remaining 2 having entered the commercialization stage. Meanwhile, the company is actively seeking out-licensing opportunities for its proprietary pipeline products and has completed 2 out-licensing agreements. Notably, HS-20093 (B7-H3), an investigational product licensed by Hansohn Pharma to GSK for overseas markets, has recently received Breakthrough Therapy Designation from the U.S. FDA.

Looking to the future, Hansoh Pharma stated that it will always adhere to high-quality innovation and excellent operations, actively collaborate with global partners, and accelerate the development, production, and commercialization of new drugs. With more breakthrough innovative therapies, it aims to benefit a wide range of patients.